2023
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review
Doernberg S, Arias C, Altman D, Babiker A, Boucher H, Creech C, Cosgrove S, Evans S, Fowler V, Fritz S, Hamasaki T, Kelly B, Leal S, Liu C, Lodise T, Miller L, Munita J, Murray B, Pettigrew M, Ruffin F, Scheetz M, Shopsin B, Tran T, Turner N, Williams D, Zaharoff S, Holland T, Patel R, King H, Kinamon T, Dai W, Geres H, Deckard N, Schuler C, Bunn I, Sharma S, Wickward C, Waller J, Wilson H, Mehigan M, Ghazaryan V, Raterman E, Samuel T, Lee M. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. Clinical Infectious Diseases 2023, 77: s295-s304. PMID: 37843115, PMCID: PMC10578051, DOI: 10.1093/cid/ciad565.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupMRSA bloodstream infectionsMethicillin-resistant Staphylococcus aureusBloodstream infectionsClinical trialsPediatric community-acquired pneumoniaInfection researchEnterococcal bloodstream infectionsOptimal vancomycin dosingOptimization of dosingRole of dalbavancinCommunity-acquired pneumoniaShort-course therapyInterventional clinical trialsVancomycin-resistant enterococciVancomycin dosingPositive infectionsNovel agentsLife measuresTreat infectionsClinical practiceNarrative reviewInfectionPositive bacteriaStaphylococcus aureus
2022
Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia
Pettigrew MM, Kwon J, Gent JF, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Pan Q, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Fowler VG, Chambers HF, Huskins WC. Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia. MBio 2022, 13: e00195-22. PMID: 35323040, PMCID: PMC9040816, DOI: 10.1128/mbio.00195-22.Peer-Reviewed Original ResearchConceptsCommunity-acquired pneumoniaShort-course strategyBeta-lactam therapyTreatment strategiesAntibiotic useRespiratory microbiomePediatric community-acquired pneumoniaDays of antibioticsShorter antibiotic coursesStandard-strategy groupDays of therapyStandard treatment strategyAntibiotic resistanceAdditional rationaleEffectiveness of interventionsImpact of durationAntibiotic coursesThroat swabsCourse strategyAntibiotic treatmentPediatric pneumoniaCourse treatmentLow prevalencePneumoniaAntibiotic resistance determinantsGastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia
Kwon J, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Chambers HF, Fowler VG, Huskins WC, Pettigrew M. Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. The Journal Of Infectious Diseases 2022, 226: 1109-1119. PMID: 35249113, PMCID: PMC9492313, DOI: 10.1093/infdis/jiac082.Peer-Reviewed Original ResearchConceptsAAD groupAntibiotic-associated diarrheaCommunity-acquired pneumoniaCommon side effectsStudy days 1Days of diarrheaPatient characteristicsAntibiotic therapyNineteen childrenStool samplesSide effectsDay 1Microbiome disruptionMicrobiota profilesGastrointestinal microbiotaMicrobiota characteristicsDiarrheaBacteroides speciesPneumoniaChildrenAntibioticsΒ-lactamsAADBaseline abundanceDysbiosisShort- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children
Williams DJ, Creech CB, Walter EB, Martin JM, Gerber JS, Newland JG, Howard L, Hofto ME, Staat MA, Oler RE, Tuyishimire B, Conrad TM, Lee MS, Ghazaryan V, Pettigrew MM, Fowler VG, Chambers HF, Zaoutis TE, Evans S, Huskins WC, Team A. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children. JAMA Pediatrics 2022, 176: 253-261. PMID: 35040920, PMCID: PMC8767493, DOI: 10.1001/jamapediatrics.2021.5547.Peer-Reviewed Original ResearchConceptsChildhood community-acquired pneumoniaAntibiotic-associated adverse effectsShort-course strategyClinical responseAdverse effectsDouble-blind placebo-controlled clinical trialPlacebo-controlled clinical trialEnd pointDays of antibioticsEarly clinical improvementInadequate clinical responseOutpatient antibiotic therapyShorter antibiotic durationsSimilar clinical responseCommunity-acquired pneumoniaPrimary end pointComposite end pointResolution of symptomsAntibiotic treatment strategiesSubset of childrenAntibiotic daysAntibiotic durationClinical improvementAntibiotic therapyInitial treatment
2020
175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)
Williams D, Creech C, Walter E, Martin J, Gerber J, Newland J, Howard L, Hofto M, Staat M, Oler R, Conrad T, Tuyishimire B, Pettigrew M, Fowler V, Chambers H, Zaoutis T, Evans S, Huskins W. 175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP). Open Forum Infectious Diseases 2020, 7: s216-s216. PMCID: PMC7776421, DOI: 10.1093/ofid/ofaa439.485.Peer-Reviewed Original ResearchShort-course therapyCourse therapyAntibiotic exposureClinical improvementOutpatient therapyAdverse effectsDouble-blind Controlled TrialPlacebo-controlled superiority trialDays of antibioticsInitial clinical improvementShort antibiotic exposureShorter antibiotic coursesCommunity-acquired pneumoniaStart of therapyCAP treatmentChildren ages 6Antibiotic coursesInitial therapyAcquired PneumoniaBaseline characteristicsClinical responseSecondary outcomesStandard therapyControlled TrialsPrimary outcome
2016
Association of sputum microbiota profiles with severity of community-acquired pneumonia in children
Pettigrew MM, Gent JF, Kong Y, Wade M, Gansebom S, Bramley AM, Jain S, Arnold SL, McCullers JA. Association of sputum microbiota profiles with severity of community-acquired pneumonia in children. BMC Infectious Diseases 2016, 16: 317. PMID: 27391033, PMCID: PMC4939047, DOI: 10.1186/s12879-016-1670-4.Peer-Reviewed Original ResearchConceptsCommunity-acquired pneumoniaCAP severityMicrobiota profilesClinical courseRespiratory microbiotaPediatric community-acquired pneumoniaIntensive care unit admissionNasopharyngeal/oropharyngeal samplesCare unit admissionOdds of lengthInduced sputum samplesRespiratory tract microbiotaOP samplesRibosomal RNA sequencingUnit admissionDecreased oddsSputum samplesChildren 6Oropharyngeal samplesMicrobiota influenceChildren 5Logistic regressionSputumSeverityPneumonia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply